Skip to content

Hydroxychloroquine for Post-Exposure Prophylaxis of COVID-19 among naval personnel: a placebo-controlled, randomized, clinical trial

Hydroxychloroquine for Post-Exposure Prophylaxis of COVID-19 among naval personnel: a placebo-controlled, randomized, clinical trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
SLCTR
Registry ID
SLCTR/2020/011
Enrollment
Unknown
Registered
2020-05-04
Start date
2020-05-04
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-exposure prophylaxis for COVID-19

Interventions

This will be a placebo-controlled, randomized, clinical trial. The study will be carried out among all eligible persons meeting the inclusion/exclusion criteria directed to be quarantined in quarant

Sponsors

Department of Medicine, Faculty of Medicine, University of Kelaniya
Lead Sponsor
State Pharmaceuticals Manufacturing Corporation (SPMC), Sri Lanka
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. All consenting male and female adult Naval personnel (18-59.9 years of age) 2. Exposure to a patient with confirmed COVID-19 infection (rRT-PCR positive for SARS-CoV-2 virus) 3. The exposure should be for >30 mins within 2 meters of the infected individual and should be within ONE WEEK at the time of inclusion in the study 4. Recruited within 48 hours of admission to these centers 5. Willing to take study drug as directed for 5 days.

Exclusion criteria

Exclusion criteria: 1. Pregnant females 2. Suspected or confirmed to have COVID-19 infection (i.e Navy personnel having positive rRT-PCR test for COVID-19 or presence of fever with cough, shortness of breath, sore throat, anosmia or diarrhoea at the time of recruitment) 3. Presence of pre-existing cardiovascular disease including being on medication for ischaemic heart disease 4. Presence of contraindication to the use of HCQ (on other medications predisposing to long QT or presence of long QT on baseline ECG) 5. Prior diagnosis of retinopathy, G6PD, malignancy or advanced kidney disease 6. Known sensitivity or allergy to Hydroxychloroquine

Design outcomes

Primary

MeasureTime frame
Number of participants symptomatic for COVID-19. (Symptomatic illness will be defined as presence of fever with cough, shortness of breath, sore throat, anosmia or diarrhoea) [Time frame: from the time of recruitment until the completion of 14 days] Number of participants testing positive for SARS-CoV-2 virus using rRT-PCR [ Time frame: day 14 from the time of recruitment]

Secondary

MeasureTime frame
None []

Countries

Sri Lanka

Contacts

Public ContactNiriella MA

Professor in Gastroenterology

maduniln@yahoo.co.uk+94 11 2961000

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 9, 2026